Myovant Sciences (NYSE: MYOV) and Cardiome Pharma (NASDAQ:CRME) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability.

Volatility and Risk

Myovant Sciences has a beta of -2.42, suggesting that its share price is 342% less volatile than the S&P 500. Comparatively, Cardiome Pharma has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.


This table compares Myovant Sciences and Cardiome Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Myovant Sciences N/A -53.75% -48.90%
Cardiome Pharma -112.91% -94.68% -40.25%

Valuation & Earnings

This table compares Myovant Sciences and Cardiome Pharma’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Myovant Sciences N/A N/A -$83.44 million ($1.41) -8.24
Cardiome Pharma $25.26 million 2.04 -$19.61 million ($0.84) -1.77

Cardiome Pharma has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Cardiome Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Myovant Sciences and Cardiome Pharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myovant Sciences 0 0 4 0 3.00
Cardiome Pharma 0 0 4 0 3.00

Myovant Sciences presently has a consensus price target of $22.50, suggesting a potential upside of 93.63%. Cardiome Pharma has a consensus price target of $6.42, suggesting a potential upside of 330.65%. Given Cardiome Pharma’s higher probable upside, analysts plainly believe Cardiome Pharma is more favorable than Myovant Sciences.

Institutional and Insider Ownership

79.2% of Myovant Sciences shares are owned by institutional investors. Comparatively, 52.5% of Cardiome Pharma shares are owned by institutional investors. 2.8% of Myovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


Cardiome Pharma beats Myovant Sciences on 6 of the 10 factors compared between the two stocks.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

Cardiome Pharma Company Profile

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with's FREE daily email newsletter.